All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
Bayer gets FDA approval for finerenone to treat heart failure with LVEF
Finerenone is the only non-steroidal mineralocorticoid receptor antagonist approved in the US for both chronic kidney disease with diabetes and heart failure with LVEF.
ViiV Healthcare expands MPP licensing deal for long-acting HIV treatment
The move aims to facilitate the development, manufacture, and supply of generic versions of CAB LA for HIV treatment in 133 countries.
RayzeBio’s new hub revolutionizes cancer treatment with next-gen RPTs
The site offers on-demand manufacturing with direct delivery to the patient’s treatment facility within just three days of release after production.
Elegen, Nutcracker unveil cell-free RNA manufacturing pilot
The initiative aims to enhance the accessibility and scalability of PCTs by reducing turnaround times and bioburden and endotoxin risks.
CEL-SCI collaboration to advance Multikine access in Saudi Arabia
CEL-SCI’s new Saudi partner will begin regulatory and commercial activities, including filing a Breakthrough Medicine Designation application with the SFDA.
Valneva Announces Lifting of European Medicines Agency’s Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ in Elderly
The committee initiated its review at the beginning of May following the occurrence of serious side effects mainly in elderly people with several underlying medical conditions.
AbbVie, IGI sign licensing deal for cancer drug ISB 2001
AbbVie gains exclusive rights to develop, manufacture, and commercialise ISB 2001 across North America, Europe, Japan, and Greater China.
EC approves Tevimbra plus chemo to treat nasopharyngeal cancer
The EC approval expands Tevimbra indications to include adults with metastatic or recurrent NPC who are not eligible for curative surgery.
Merck to acquire UK drugmaker Verona Pharma for $10bn
Merck will add Ohtuvayre (ensifentrine), a selective dual inhibitor of phosphodiesterase 3 and 4 (PDE3 and PDE4), into its cardio-pulmonary pipeline.
Zentiva, Lupin collaborate on commercialising Certolizumab Pegol
The partnership aims to commercialise Certolizumab Pegol, a TNF alpha inhibitor intended to treat arthritis, plaque psoriasis, and Crohn’s disease.